Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs).
To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC.